Literature DB >> 30835073

C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.

Joyita Bharati1, Divya Bhatia1, Priyanka Khandelwal1, Nandita Gupta2, Aditi Sinha1, Rajesh Khadgawat2, Pankaj Hari1, Arvind Bagga3.   

Abstract

Fibroblast growth factor-23 (FGF23) is central to phosphate homeostasis. The author examined if blood levels of FGF23 allow discrimination of classic hypophosphatemic rickets from other causes of non-nutritional rickets with hypophosphatemia. Forty-two children (median age: 102 mo) with non-nutritional rickets and hypophosphatemia were clinically classified as having distal renal tubular acidosis (RTA, n = 12), Fanconi syndrome (n = 8), classic hypophosphatemic rickets (n = 11), vitamin D dependent rickets (n = 7) and Dent disease (n = 4). Median blood FGF23 (measured by C-terminal ELISA) concentrations were similar in all groups (P = 0.24). These levels did not correlate with phosphate, tubular maximum for phosphate, calcium, 25-hydroxyvitamin D, creatinine, and parathormone levels. Patients with distal RTA showed variable degree of proximal tubular dysfunction that resolved following alkali supplements. Blood FGF23 levels did not satisfactorily differentiate classic hypophosphatemic rickets from other causes of hypophosphatemic rickets.

Entities:  

Keywords:  Dent disease; Familial rickets; Hypophosphatemia; Renal tubular acidosis

Mesh:

Substances:

Year:  2019        PMID: 30835073     DOI: 10.1007/s12098-019-02909-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

Review 1.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

2.  Nomogram for derivation of renal threshold phosphate concentration.

Authors:  R J Walton; O L Bijvoet
Journal:  Lancet       Date:  1975-08-16       Impact factor: 79.321

3.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

4.  Atypical presentation of distal renal tubular acidosis in two siblings.

Authors:  Velibor Tasic; Petar Korneti; Zoran Gucev; Bernd Hoppe; Nenad Blau; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2008-04-02       Impact factor: 3.714

5.  FGF23 is elevated in Gambian children with rickets.

Authors:  Ann Prentice; Mustapha Ceesay; Shailja Nigdikar; Stephen J Allen; John M Pettifor
Journal:  Bone       Date:  2007-12-08       Impact factor: 4.398

6.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Journal:  Bone       Date:  2008-03-05       Impact factor: 4.398

7.  [Clinical usefulness of the determination of fibroblast growth factor 23 in the evaluation of patients with osteomalacia].

Authors:  Laia Gifre; Maria Jesús Martínez de Osaba; Ana Monegal; Núria Guañabens; Pilar Peris
Journal:  Med Clin (Barc)       Date:  2014-03-13       Impact factor: 1.725

8.  Iron status and fibroblast growth factor-23 in Gambian children.

Authors:  Vickie Braithwaite; Landing M A Jarjou; Gail R Goldberg; Ann Prentice
Journal:  Bone       Date:  2012-03-16       Impact factor: 4.398

9.  Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.

Authors:  Vickie Braithwaite; Kerry S Jones; Shima Assar; Inez Schoenmakers; Ann Prentice
Journal:  Endocr Connect       Date:  2013-12-19       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.